Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2 3Phase 1 2Phase EARLY_PHASE1 1

Status

Completed 7Recruiting 6Terminated 5Withdrawn 4Active not recruiting 3Unknown 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 1Other solid neoplasm 1Lymphoid 1

Conditions

Recurrence 2Solid Tumor Malignancy 1Recurrent Squamous Cell Lung Carcinoma 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cyclophosphamide 28pembrolizumab 22Bevacizumab 18Fluorouracil 17Cisplatin 17Nivolumab 16Capecitabine 16Leucovorin 15Dexamethasone 14Carboplatin 13avelumab 12Oxaliplatin 12Radiosurgery 11Gemcitabine 11Rituximab 10Radiotherapy 10Lenalidomide 10ALT-803 10venetoclax 9fludarabine 9Taxes 9Omacor 9Azacitidine 9130-nm albumin-bound paclitaxel 9Paclitaxel 8Docetaxel 8Bortezomib 8fludarabine phosphate 7Melphalan 7Irinotecan 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Withdrawn × selinexor × Clear all
NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Karyopharm Therapeutics Inc

Phase 1/2 Withdrawn
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02389543 2023-01-26

SLAM

Karyopharm Therapeutics Inc

Phase 1/2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence

NCT05177276 2022-01-04

Selinexor Combination Ph 1 Study

Hackensack Meridian Health

Phase 1/2 Withdrawn
Other solid neoplasm

Solid Tumor Malignancy

NCT02536495 2015-10-30

Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer

Ohio State University Comprehensive Cancer Center

Phase 1/2 Withdrawn

Recurrent Squamous Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡